Stanislaw Burzynski - Burzynski Research Chairman of the Board and Presidentident
| BZYR Stock | USD 0.04 0.01 28.57% |
Chairman
Dr. Stanislaw R. Burzynski, M.D., Ph.D., is Chairman of the Board, President of the Company. He was the President and Chairman of the Board of Directors of the Company since its inception in 1984. He also served as the Companys Secretary and Treasurer until March 1, 2012. Dr. Burzynski is a physician in private practice in Houston, Texas specializing in the treatment of cancer. Currently listed in Whos Who In The World and a member in standing with both the American and World Medical Associations, Dr. Burzynski is an internationally recognized physician and scientist who has pioneered the development and use of biologically active peptides in diagnosing, preventing, and treating cancer since 1967. In 1967, Dr. Burzynski graduated with distinction with an M.D. degree from the Medical Academy in Lublin, Poland, finishing first in his class of 250, and he subsequently earned his Ph.D. in Biochemistry. From 1970 to 1977, he was a researcher and Assistant Professor at Baylor College of Medicine in Houston. At Baylor, Dr. Burzynskis research was sponsored and partially funded by the National Cancer Institute. Also at Baylor, he authored and coauthored sixteen publications, including five concerning his research on peptides and their effect on human cancer. Four of these publications were also coauthored by other doctors associated with M.D. Anderson Hospital and Tumor Institute and Baylor College of Medicine. In May 1977, Dr. Burzynski received a Certificate of Appreciation from Baylor College of Medicine and in that same year founded the Company. Dr. Burzynski is a member of the American Medical Association, American Association for Cancer Research, Harris County Medical Society, New York Academy of Sciences, Society for Neuroscience, Texas Medical Association, the Society of Sigma Xi, and the Society of Neurooncology. since 2012.
| Age | 80 |
| Tenure | 12 years |
| Phone | 713 335 5697 |
| Web | https://www.burzynskiclinic.com |
Burzynski Research Management Efficiency
The company has return on total asset (ROA) of (127.6631) % which means that it has lost $127.6631 on every $100 spent on assets. This is way below average. Burzynski Research's management efficiency ratios could be used to measure how well Burzynski Research manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Stephen Glover | ZyVersa Therapeutics | 64 | |
| David Hochman | Orchestra BioMed Holdings | 49 | |
| John Crowley | Amicus Therapeutics | 57 | |
Management Performance
| Return On Asset | -127.66 |
Burzynski Research Leadership Team
Elected by the shareholders, the Burzynski Research's board of directors comprises two types of representatives: Burzynski Research inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Burzynski. The board's role is to monitor Burzynski Research's management team and ensure that shareholders' interests are well served. Burzynski Research's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Burzynski Research's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patryk Goscianski, Treasurer, Secretary | ||
| Stanislaw Burzynski, Chairman of the Board and Presidentident |
Burzynski Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Burzynski Research a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -127.66 | |||
| Current Valuation | 2.65 M | |||
| Shares Outstanding | 131.45 M | |||
| Shares Owned By Insiders | 81.00 % | |||
| Price To Earning | (5.25) X | |||
| Price To Book | 2,191 X | |||
| EBITDA | (976.66 K) | |||
| Net Income | (976.66 K) | |||
| Cash And Equivalents | 1.27 K | |||
| Current Ratio | 0.11 X |
Pair Trading with Burzynski Research
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Burzynski Research position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Burzynski Research will appreciate offsetting losses from the drop in the long position's value.Moving against Burzynski Pink Sheet
| 0.5 | TLKMF | Telkom Indonesia Tbk | PairCorr |
| 0.36 | BAC | Bank of America Aggressive Push | PairCorr |
| 0.33 | SSNLF | Samsung Electronics | PairCorr |
| 0.33 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Burzynski Research could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Burzynski Research when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Burzynski Research - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Burzynski Research to buy it.
The correlation of Burzynski Research is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Burzynski Research moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Burzynski Research moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Burzynski Research can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Burzynski Pink Sheet Analysis
When running Burzynski Research's price analysis, check to measure Burzynski Research's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Burzynski Research is operating at the current time. Most of Burzynski Research's value examination focuses on studying past and present price action to predict the probability of Burzynski Research's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Burzynski Research's price. Additionally, you may evaluate how the addition of Burzynski Research to your portfolios can decrease your overall portfolio volatility.